GT201300040A - Quelatos de oligonucleótidos - Google Patents

Quelatos de oligonucleótidos

Info

Publication number
GT201300040A
GT201300040A GT201300040A GT201300040A GT201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A
Authority
GT
Guatemala
Prior art keywords
oligonucleotide
divalent
chelation
cations
cheats
Prior art date
Application number
GT201300040A
Other languages
English (en)
Inventor
Vaillant Andrew
Bazinet Michel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300040(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300040A publication Critical patent/GT201300040A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE DIVULGACIÓN DESCRIBE LA QUELACIÓN AMPLIAMENTE ACTIVA DE DIVERSOS CATIONES METÁLICOS DIVALENTES 2+ MEDIANTE CUALQUIER OLIGONUCLEÓTIDO (ON), SIN IMPORTAR EL TAMAÑO O LA MODIFICACIÓN. ESTE EFECTO DE QUELACIÓN ES ESPECÍFICO PARA CATIONES QUE SON DIVALENTES (O DE VALENCIA MAYOR) Y DA COMO RESULTADO LA FORMACIÓN DE QUELATOS DE OLIGONUCLEÓTIDOS QUE NO SE COMPORTAN COMO SALES.SE DESCRIBE EN LA PRESENTE UNA COMPOSICIÓN NOVEDOSA DE UN QUELATO DE ON PREPARADO USANDO CUALQUIER ON Y UN CATIÓN METÁLICO DIVALENTE Y MÉTODOS PARA SUPRIMIR LA ANTICOAGULACIÓN Y/O LAS REACCIONES EN EL SITIO DE INYECCIÓN SUBCUTÁNEA Y/O TOLERABILIDAD MEJORADA CON OLIGONUCLEÓTIDOS MEDIANTE EL USO DE QUELATOS DE ON DURANTE LA ADMINISTRACIÓN DE OLIGONUCLEÓTIDOS
GT201300040A 2010-08-20 2013-02-14 Quelatos de oligonucleótidos GT201300040A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
GT201300040A true GT201300040A (es) 2014-09-02

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300040A GT201300040A (es) 2010-08-20 2013-02-14 Quelatos de oligonucleótidos

Country Status (35)

Country Link
US (2) US8513211B2 (es)
EP (1) EP2605794B1 (es)
JP (1) JP5775581B2 (es)
KR (3) KR20150082685A (es)
CN (2) CN103768086B (es)
AU (1) AU2011291401B2 (es)
BR (1) BR112013003875B1 (es)
CA (2) CA2855690C (es)
CL (1) CL2013000445A1 (es)
CO (1) CO6670525A2 (es)
CR (1) CR20130069A (es)
CU (1) CU20130022A7 (es)
CY (1) CY1118207T1 (es)
DK (1) DK2605794T3 (es)
DO (1) DOP2013000041A (es)
EA (1) EA026660B1 (es)
EC (1) ECSP13012449A (es)
ES (1) ES2598556T3 (es)
GT (1) GT201300040A (es)
HK (2) HK1184058A1 (es)
HR (1) HRP20161333T1 (es)
HU (1) HUE029521T2 (es)
IL (1) IL224237A (es)
LT (1) LT2605794T (es)
MX (1) MX340294B (es)
MY (1) MY160961A (es)
NZ (1) NZ606364A (es)
PL (1) PL2605794T3 (es)
PT (1) PT2605794T (es)
RS (1) RS55245B1 (es)
SG (1) SG187165A1 (es)
SI (1) SI2605794T1 (es)
SM (1) SMT201600370B (es)
WO (1) WO2012021985A1 (es)
ZA (1) ZA201300497B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660523C (en) 2006-08-11 2019-03-19 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
ES2619314T3 (es) 2007-05-11 2017-06-26 Adynxx, Inc. Expresión génica y dolor
HUE028662T2 (en) 2007-10-26 2016-12-28 Academisch Ziekenhuis Leiden Preparations and methods for controlling muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
SI2841578T1 (sl) 2012-04-23 2017-12-29 Biomarin Technologies B.V. Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenj
JP6251247B2 (ja) 2012-05-10 2017-12-20 エーダイニクス インコーポレイテッド 活性成分の送達のための製剤
SG11201407599SA (en) * 2012-05-18 2014-12-30 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
RU2674600C2 (ru) 2012-07-03 2018-12-11 Просенса Текнолоджиз Б.В. Олигонуклеотид для лечения пациентов с мышечной дистрофией
CN104837501B (zh) * 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
MD4760C8 (ro) 2014-07-10 2022-02-28 Replicor Inc. Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
SI3286203T1 (sl) 2015-04-23 2020-10-30 Geron Corporation Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli
BR112021008539A2 (pt) * 2018-11-08 2021-08-03 Aligos Therapeutics, Inc. polímeros de oligonucleotídeos e métodos de inibição de transporte de antígeno s
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
AU2021383758A1 (en) * 2020-11-20 2023-06-15 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
EP4367241A1 (en) 2021-07-09 2024-05-15 GlaxoSmithKline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019429A4 (en) * 1997-08-20 2001-08-08 Somagenics Inc ANTISENSE THERAPEUTIC PRODUCTS WITH IMPROVED BINDING PROPERTIES AND METHODS OF USE
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US20070105116A1 (en) * 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid
US20060293510A1 (en) * 2003-09-08 2006-12-28 Japan Science And Technology Agency Metal complex type nucleic acid
JP2009500020A (ja) * 2005-07-01 2009-01-08 バイオヴェリス コーポレイション 核酸を検出、増幅および／また単離するための組成物および方法
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Also Published As

Publication number Publication date
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
BR112013003875A2 (pt) 2018-03-13
US20120046348A1 (en) 2012-02-23
ZA201300497B (en) 2013-09-25
US8513211B2 (en) 2013-08-20
CL2013000445A1 (es) 2013-11-22
CA2806616C (en) 2015-08-11
SG187165A1 (en) 2013-02-28
CO6670525A2 (es) 2013-05-15
CN103768086B (zh) 2015-10-14
HRP20161333T1 (hr) 2016-12-02
MX340294B (es) 2016-07-04
EA201300259A1 (ru) 2013-12-30
EA026660B1 (ru) 2017-05-31
CN103052405B (zh) 2015-11-25
WO2012021985A1 (en) 2012-02-23
US8716259B2 (en) 2014-05-06
DOP2013000041A (es) 2017-12-15
CA2806616A1 (en) 2012-02-23
EP2605794A4 (en) 2014-07-02
JP2013536195A (ja) 2013-09-19
CN103768086A (zh) 2014-05-07
EP2605794A1 (en) 2013-06-26
IL224237A (en) 2015-09-24
SMT201600370B (it) 2016-11-10
NZ606364A (en) 2014-12-24
PT2605794T (pt) 2016-10-25
MY160961A (en) 2017-03-31
JP5775581B2 (ja) 2015-09-09
AU2011291401B2 (en) 2014-11-27
MX2013001668A (es) 2013-07-22
US20130296410A1 (en) 2013-11-07
KR20150039873A (ko) 2015-04-13
BR112013003875B1 (pt) 2021-10-05
KR101606495B1 (ko) 2016-03-28
HK1198123A1 (en) 2015-03-13
AU2011291401A1 (en) 2013-01-10
SI2605794T1 (sl) 2017-01-31
HK1184058A1 (zh) 2014-01-17
CR20130069A (es) 2013-09-20
EP2605794B1 (en) 2016-07-20
HUE029521T2 (en) 2017-03-28
LT2605794T (lt) 2016-10-25
CU20130022A7 (es) 2013-04-19
KR20150082685A (ko) 2015-07-15
CA2855690A1 (en) 2012-02-23
CN103052405A (zh) 2013-04-17
RS55245B1 (sr) 2017-02-28
ECSP13012449A (es) 2013-04-30
KR20130099067A (ko) 2013-09-05
CA2855690C (en) 2015-08-25
DK2605794T3 (en) 2016-10-24
PL2605794T3 (pl) 2017-01-31

Similar Documents

Publication Publication Date Title
GT201300040A (es) Quelatos de oligonucleótidos
AR091604A1 (es) Potenciacion de autofagia o aumento de longevidad por administracion de urolitinas o precursores de las mismas, compuesto
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
EA201201648A1 (ru) Стимуляторы sgc
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2015017532A (es) Métodos para modular la actividad del regulador de transmembrana de fibrosis quística.
EA201591767A1 (ru) Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
PE20210949A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EP4335507A3 (en) Combination therapy
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
AR093794A1 (es) Composiciones conteniendo fosfato de zinc
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
MX343160B (es) Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
CO2017001025A2 (es) Métodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la pérdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes
UY31849A (es) Nuevos compuestos como inhibidores de pde4
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
ECSP14011792A (es) Inhibidores de iap
BR112012022243A2 (pt) terapias inibidoras de autografia baseadas em tioxantona para tratar câncer
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
WO2014205127A3 (en) Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
MX2017008143A (es) Complejo de zinc fosfato para el cuidado bucal.